Glucagon-Like Peptide-1 Secretory Function as an Independent Determinant of Blood Pressure: Analysis in the Tanno-Sobetsu Study

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Yoshihara, Mayumi ^a   Akasaka, Hiroshi ^a   Ohnishi, Hirofumi ^a   Miki, Takayuki ^a   Furukawa, Tetsuaki ^a   Yuda, Satoshi ^a   Saitoh, Shigeyuki ^b   Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING METABOLISM; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARDIOVASCULAR AGENT; CHOLESTEROL; CREATININE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; MEDICAL EXAMINATION; METABOLIC DISORDER; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; ADAPTATION; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; BLOOD; BLOOD PRESSURE; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SECRETION (PROCESS);

ADAPTATION, PHYSIOLOGICAL; AGED; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BLOOD GLUCOSE; BLOOD PRESSURE; COHORT STUDIES; FASTING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED;

EID: 84879740850     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067578     Document Type: Article

References (43)

1. Baggio LL, Druncker DJ, (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157.
2. Ravassa S, Zudaire A, Díez J, (2012) GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res 94: 316-323.
3. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, et al. (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86: 3717-3723.
4. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ 2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50: 609-613.
5. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, et al. (2004) Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89: 3055-3061.
6. Gutzwiller JP, Hruz P, Huber A, Hamel C, Zehnder C, et al. (2006) Glucagon-like peptide 1 is involved in sodium and water homeostasis in humans. Digestion 73: 142-150.
7. Yu M, Moreno C, Hoagland K, Dahly A, Ditter K, et al. (2003) Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 21: 1125-1135.
8. Garber A, Henry R, Ratner R, Garcia-Hernandez P, Rodriguez-Pattzi H, et al. (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373: 473-481.
9. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, et al. (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32: 1224-1230.
10. Blonde L, Russell-Jones D, (2009) The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes, Obesity and Metabolism 11: 26-34.
11. Okerson T, Yan P, Stonehouse A, Brodows R, (2010) Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 23: 334-339.
12. Ohnishi H, Saitoh S, Takagi S, Katoh N, Chiba Y, et al. (2006) Incidence of type 2 diabetes in individuals with central obesity in a rural Japanese population: the Tanno and Sobetsu Study. Diabetic Care 29: 1128-1129.
13. Mitsumata K, Saitoh S, Ohnishi H, Akasaka H, Miura T, (2012) Effects of parental hypertension on longitudinal trends in blood pressure and plasma metabolic profile: mixed-effects model analysis. Hypertension 60: 1124-1130.
14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
16. Matsuda M, DeFronzo RA, (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470.
17. Jørgensen JO, Rosenfalck AM, Fisker S, Nyholm B, Fineman MS, et al. (2000) Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: a placebo-controlled study. Eur J Endocrinol 143: 593-599.
18. Pannacciulli N, Bunt JC, Koska J, Bogardus C, Krakoff J, (2006) High fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutri 84: 556-560.
19. Adam TC, Jocken J, Westerterp-Plantenga MS, (2005) Decreased glucagon like peptide 1 release after weight loss in overweight/obese subjects. Obes Res 13: 710-716.
20. De Luis D, Pacheco D, Conde R, Primo D, Aller R, et al. (2012) Basal GLP-1 levels in morbidity obese patients following biliopancreatic diversion surgery. Ann Nutr Metab 61: 70-73.
21. Carroll JF, Kaiser KA, Franks SF, Deere C, Caffrey JL, (2007) Influence of BMI and gender on postprandial hormone responses. Obesity 15: 2974-2983.
22. Korosi J, McIntosh CH, Pederson RA, Demuth HU, Habener JF, et al. (2001) Effect of aging and diabetes on the enteroinsular axis. J Gerontol A Biol Sci Med Sci 56: M575-579.
23. Tahara N, Yamagishi S, Takeuchi A, Tahara A, Kaifu K, et al. (2013) Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans. Clin Biochem 46: 300-303.
24. Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, et al. (2006) An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol 46: 635-641.
25. Schusdziarra V, (1988) Physiological significance of gastrointestinal somatostatin. Horm Res 29: 75-78.
26. Li W, Shi YH, Yang RL, Cui J, Xiao Y, et al. (2010) Effect of somatostatin analog on high-fat diet-induced metabolic syndrome: involvement of reactive oxygen species. Peptides 31: 625-629.
27. Lim GE, Huang GJ, Flora N, LeRoith D, Rhodes CJ, et al. (2009) Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology 150: 580-591.
28. Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, et al. (2011) Extendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 405: 79-84.
29. Hirata Y, Kurobe H, Nishio C, Tanaka K, Fukuda D, et al. (2013) Extendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury. Eur J Pharmacol 699: 106-111.
30. Dong Z, Chai W, Wang W, Zhao L, Fu Z, et al. (2013) Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment. Am J Physiol Endocrinol Metab 304: E222-228.
31. Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, et al. (2012) Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol 303: F963-971.
32. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, et al. (2013) GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19: 567-575.
33. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, et al. (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrionol Metab 287: E1209-1215.
34. Tesauro M, Barini A, Schinzari F, Pitocco D, Adamo A, et al. (2013) Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care 36: 683-689.
35. Yerram P, Whaley-Connell A, (2012) Novel role for the incretins in blood pressure regulation. Curr Opin Nephrol Hypertens 21: 463-468.
36. Bharucha AE, Charkoudian N, Andrews CN, Camilleri M, Sletten D, et al. (2008) Effects of glucagon-like peptide-1, yohimbine and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 295: R874-880.
37. Edwards CM, Todd JF, Ghatei MA, Bloom SR, (1998) Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycemia in fasted healthy subjects. Clin Sci 95: 719-724.
38. Mendis B, Simpson E, MacDonald I, Mansell P, (2012) Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol 74: 437-444.
39. Hattori Y, Jojima T, Tomizawa A, Satoh H, Hattori S, et al. (2010) A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory actions in endothelial cells. Diabetologia 53: 2256-2263.
40. Erdogdu O, Nathanson D, Sjöholm A, Nyström T, Zhang Q, (2010) Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA-, and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 325: 26-35.
41. Oesburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, et al. (2010) Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of the activation of protein kinase A. Arterioscler Thromb Vasc Biol. 30: 1407-1414.
42. Akasaka H, Ohnishi H, Saitoh S, Shimamoto K, Miura T, (2012) Relationship between blood pressure and oxidative stress via sodium intake: the Tanno and Sobetsu Study. [Abstract] J Hypertens 30: e303.
43. Kawano Y, Tsuchihashi T, Matsuura H, Ando K, Fujita T, et al. (2007) Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (2) Assessment of salt intake in the management of hypertension. Hypertens Res 30: 887-893.